INTRODUCTION:
The stem cell niche is a complex signaling microenvironment that acts locally to sustain stem cell activity in tissue maintenance and regeneration. Although the cellular constitution and signaling activity of the stem cell niche is coming into focus in a variety of tissues, genetic regulatory factors that specify the niche are less clear. The activity of such factors is particularly intriguing in organs such as the breast, where the niche provides local signals for tissue homeostasis but also must be entrained by circulating hormones that induce the dramatic changes of puberty.
RATIONALE:
The epithelial stem cells of a variety of organs respond to secreted signals generated in subjacent stromal cells, in a manner often dependent on activity of the Hedgehog (Hh) signaling pathway. Gli2, which encodes the major transcriptional effector of Hh signaling, is expressed in a subset of stromal cells adjacent to the ductal epithelium of the mouse mammary gland and is highly expressed at terminal end buds and end structures of the pubertal and adult mammary gland, respectively, which represent the sites of mammary epithelial stem cells.
RESULTS: Stromal ablation of a conditional

Gli2
fl allele with Fsp1
Cre , a stromally expressed recombinase allele (producing Gli2 DS mice), caused a delay in mammary ductal development, reduced the number of mammary gland stromal cells and volume of extracellular matrix, and caused abnormal mammary duct distension. Stromal Gli2 ablation did not alter development of the ovary or pituitary, nor their production of mammatrophic hormones such as estrogen or growth hormone, but did affect ductal regeneration, as indicated by a fivefold decrease in outgrowth efficiency of mammary stem cells (MaSCs) transplanted into Gli2 DS mammary glands. These findings suggest that Gli2 specifies a stromal niche signaling program that critically regulates MaSC activity. FACS-isolated mammary stromal cells showed Gli2-dependent expression of factors that stimulate epithelial stem cell renewal, ductal outgrowth, and morphogenesis, including specific members of the IGF, WNT, FGF, and HGF families of secreted peptides. Single-cell analysis showed expression of these factors in a subset of stromal cells in a manner dependent on Gli2 function. Receptors for the mammatrophic hormones estrogen and growth hormone were also expressed in a Gli2-dependent manner, and estrogen and growth hormone treatment of cultured stromal cells induced these secreted peptide factors, suggesting that a critical role of Gli2 in mammary stromal niche cells is to render these cells responsive to systemic mammatrophic hormones. Supporting this conclusion, mammary gland implants of polymer fragments releasing IGF1 and WNT2 rescued Gli2 DS ductal growth phenotypes, whereas growth hormone-releasing polymer did not.
CONCLUSION:
We find that the Hedgehog pathway transcriptional effector GLI2 specifies a stromal cell niche signaling program that supports mammary epithelial stem cells in pubertal and virgin adult mice. This program includes expression of factors such as IGF and WNT, and GLI2 acts in part by causing expression of receptors for hormones such as estrogen and growth hormone, thus entraining local stem cell niche activity to systemic mammatrophic hormones. Our work illustrates the central role of the stromal niche in controlling epithelial stem cell activity and suggests that niche failure may underlie pathogenesis of certain diseases, including the deficient breast development and hormonal insensitivity associated with the human disorder, combined pituitary hormone deficiency.
T he Hedgehog (Hh) signaling pathway regulates embryonic patterning and postnatal homeostasis of multiple tissues (1-3), acting via its major transcriptional effector, GLI2. A specific function for Gli2 in ductal morphogenesis of the mammary gland was suggested by the defects noted in Gli2 −/− mutant mouse embryonic mammary gland rudiments engrafted into adult hosts (4) . In addition, breast underdevelopment at puberty is associated with the human disorder CPHD (combined pituitary hormone deficiency) (5), a substantial subset of which is caused by loss-of-function or trans-dominant mutations of the GLI2 gene (6) (7) (8) . In contrast, Gli2 function appears to be dispensable for embryonic specification of mammary gland rudiments, which instead shows a requirement for expression of the GLI3 repressor of Hh pathway targets in underlying somitic mesoderm (1, (9) (10) (11) (12) . Adding further complexity to the role of Hh pathway activity, Gli2 is expressed in the epithelium of embryonic mammary gland rudiments, whereas Gli2 expression in pubertal and virgin adult mice occurs exclusively in stromal cells (12) .
Periductal Gli2 expression in developing mammary
To investigate the role of Gli2 in postnatal mammary gland growth, we examined Gli2 expression in the developing gland and manipulated its activity through genetic ablation or hyperactivation. Gli2 expression occurs intermittently along mammary ducts, and is highly enriched at terminal end buds of the pubertal gland (5 weeks; Fig. 1 , A and B) and at terminal structures of the adult female gland (10 weeks; Fig. 1 , E and F). These regions of the pubertal and adult ducts undergo extensive proliferation and have been suggested as sites for mammary epithelial stem cells (13) (14) (15) (16) (17) (18) . Gli2-expressing cells in cross sections of mammary ducts appear restricted to stromal regions in both pubertal (Fig. 1 , C and D) and adult mammary gland (Fig. 1 , G and H), as previously reported (12) , and in adult male mammary gland as well ( fig. S1A ). This stromal pattern of Gli2 RNA and protein expression was confirmed by quantitative polymerase chain reaction (qPCR) and Western blot assays of fluorescence-activated cell sorting (FACS)-sorted stromal versus luminal or basal epithelial cells (Fig. 1, I and J, and fig. S1B ). The close proximity of Gli2 expression to mammary ducts ( (Fig. 1K , right panel, blue arrowheads; see Methods). We found that transforming growth factor-b1 (TGFb1), expressed in mammary epithelial cells (19) , markedly induced expression of Gli2 in FACS-isolated stromal cells in vitro in a dose-dependent manner (4.5-fold and 8-fold at 5 and 50 ng/ml, respectively; Fig. 1L ). The dependence of Gli2 expression on TGFb1 signaling was confirmed in vivo by a 2.2-fold reduction of mammary gland stromal Gli2 mRNA upon treatment of mice with the TGFb receptor (TGFbR) inhibitor, LY2109761 (Fig. 1M ). Response to TGFb does not include expression of Gli2 in the mammary epithelium; this and other differences in epithelial versus stromal responses may help account for the complexity of TGFb effects on mammary development and in carcinogenesis (19) .
Stromal Gli2 in pubertal mammary development
To genetically ablate Gli2 function in stromal cells by site-specific recombination, we examined the extent of coincident expression of b-Gal from the Gli2 nLacZ reporter with Cre recombinase from the Fsp1
Cre allele of the fibroblast specific protein 1 gene. In mice of the genotype Fsp1 Cre driver thus appears suitable for Cre-mediated ablation of a floxed conditional allele of Gli2 (Gli2 fl ) in stromal cells of the mammary gland, which is the exclusive site of Gli2 expression in mammary glands of pubertal and virgin adult females. Fsp1 , hereafter referred to as Gli2 DS (genetic ablation of Gli2 is characterized in fig. S2A ) produced a significant delay of mammary gland development at pubertal stages (5 weeks; fig. S2B ). By adult stages, Gli2 DS mice gradually developed a hypoplastic mammary gland with greatly enlarged ducts and severely disrupted terminal end structures (6 to 10 weeks; Fig. 2C and fig. S3 ). Histological examination and FACS analysis further revealed reduced levels of type I, type II, and type IV collagen fibers and a fivefold reduction in periductal stromal cells (2.3% versus 10.9%; Fig.  2E and fig. S2C ). The combined ductal and stromal abnormality, as measured by the ratio of ductal diameter to stromal thickness (ductal:stromal ratio or DSR), was highly significant in Gli2 DS mice (Fig. 2D) .
To examine the effect of increased Gli2 activity, we used Fsp1
Cre to drive stromal expression of Smo
M2
, which encodes a constitutively activating form of the seven-transmembrane Smo component of the Hedgehog pathway (20, 21) fig. S5A ). To further investigate reduced levels of proliferation, we cultured mammary epithelial cells from Gli2 DS and
Gli2
WT mice ex vivo in a Matrigel-based colonyforming assay. We found that primary epithelial cells from Gli2 WT mice formed three times as many colonies as cells from Gli2 DS mice (Fig. 3B) .
Collectively, these data indicate that removal of Gli2 in Fsp1 Cre/+ stromal cells leads to a defect in the proliferation of the mammary epithelium.
The growth and regeneration of mammary epithelium depend on the activity of mammary epithelial stem cells (MaSCs), functionally characterized by measurement of mammary repopulating units (MRUs) upon transplantation of FACS-isolated cells into cleared mammary fat pads (22, 23) . The activity of MaSCs depends critically upon signals provided by the mammary stroma (24) . As MaSCs are enriched in myoepithelium (22, 23) , the basal layer of the mammary epithelium that directly contacts the stromal environment, we sought to investigate how stromal (22, 23) , are fluorescent red, as mT expression is not affected by the stromal Fsp1
Cre driver. These red fluorescent cells were mixed with similarly FACS-isolated green fluorescent cells [expressing enhanced GFP (EGFP)] from control mice, and the mixtures were injected into the left and right cleared fat pads, respectively, of recipient NSG animals ( Fig. 3C ). Within 9 weeks of transplantation, the red fluorescent cells from Gli2
WT mice contributed to the regenerated ductal tree to the same extent as green fluorescent control cells (44%:56%), whereas red fluorescent cells from the Gli2 DS mice contributed minimally (7%:93%) ( To further examine the effect of stromal Gli2 function on MaSCs, we measured MRUs of FACSisolated upper basal epithelial cells from GFPexpressing mice upon transplantation into cleared mammary fat pads of Gli2 DS or Gli2 WT littermate mice (Fig. 3E ). We found that transplantation into control host animals with at least one Gli2
WT allele in their mammary stroma generates ductal outgrowths fivefold more efficiently as compared to Gli2 DS hosts (outgrowth efficiencies: 1/618 versus 1/2920; Fig. 3F ). Ductal outgrowth in Gli2 DS mice was limited to a small area (<20 mm 2 ), and these outgrowths were often malformed, with enlarged mammary ducts and a thin layer of stromal cells ( Fig. 3E and fig. S5C ) with reduced Gli2 expression ( fig. S5D) . Notably, the difference in MaSC functional activity measured in these transplantation assays is solely a function of the Gli2 status of the host stromal environment, as the donor cells are from mice that are wild-type except for expression of GFP. These findings thus suggest that the Gli2 activity in FSP1+ cells controls a niche-signaling program that regulates mammary stem cell activity and that this program is disrupted in Gli2 DS mice.
Locally acting factors mediate stromal Gli2 activity
In addition to input from local stromal cells, mammary morphogenesis and the MaSC pool are also regulated by other factors, including the systemic hormonal environment (25) as well as immune cell surveillance (26) . We therefore investigated the possibility that Gli2 activity in other cells or Cell Technologies. Data are presented as mean ± SEM, and significance was calculated by an unpaired Student's t test (*P < 0.05%, **P < 0.01).
organs affects mammary development. To this end, we first analyzed coexpression of Fsp1 and Gli2 in ovary, the major organ for female hormone production (e.g., estrogen and progesterone). We observed few double-positive cells in corpus luteum (0.16%, n = 1927), and no coexpression in follicles (0%, n = 2418) (Fig. 4 , A to D), suggesting that Gli2 ablation is a rare event in the ovaries of our Gli2 DS mice. In addition, and consistent with the lack of Fsp1 and Gli2 coexpression in ovary, Gli2 WT and Gli2 DS mice had statistically indistinguishable estrogen levels ( Fig. 4E , P = 0.5) that were comparable to those previously reported (27) . We similarly noted little coexpression of Fsp1 and Gli2 in the pituitary and no significant change in serum growth hormone (GH) or prolactin levels (Fig. 4 , F to H). These data collectively suggest that the Gli2 DS mice maintain a hormonal environment similar to that of Gli2 WT littermates during development.
We next investigated potential coexpression of Fsp1 and Gli2 in mammary macrophages, which are reported to play a role in mammary development during puberty (26) . Although we did observe Gli2 expression in a minuscule fraction (~1%) of mammary cells expressing the macrophage marker F4/80 (Fig. 5A, n = 1247) , we detected no Fsp1 expression in F4/80+ cells (Fig. 5B, n = 1248 ), indicating that Fsp1
Cre -driven ablation of Gli2 in mammary macrophages is highly unlikely. To further exclude a possible defect in mammary macrophages in the Gli2 DS phenotype, we transplanted wild-type stromal cells or macrophages into the mammary fat pads of pubertal Gli2
DS
;NSG recipient mice (Fig. 5C ). We noted that although stromal cells successfully rescued ductal enlargement with restoration of periductal collagen and extracellular matrix (Fig. 5, C to F, n = 3 WT littermates by microarray analysis) and identified genes encoding paracrine factors such as Igf1, Wnt2, Hgf, Fgf7, and Bmp7; we also identified down-regulated genes encoding estrogen receptor (Esr1), growth hormone receptor (Ghr), and other genes typically expressed in stromal cells. Of particular interest among the paracrine factors, WNT signals sustain the activity of MaSCs in vivo and in ex vivo culture (28, 29) , and functional inactivation of Igf1 or its epithelially expressed receptor, Igf-1r, leads to development of hypoplastic mammary glands with terminal end bud abnormalities (30, 31) , similar to the defects we observe in Gli2 DS mice. The down-regulation of these genes was confirmed by qRT-PCR of bulk stromal cells from Gli2 WT and Gli2 DS mice (Fig. 6A) and was further quantified by qRT-PCR from single cells ( fig. S6 ; summarized in Fig. 6B ). Igf1 and Wnt2 were expressed in 7% and 9% of individual Gli2 WT stromal cells, respectively, but in 0% of Gli2 DS stromal cells (Fig. 6B) . Our single-cell analysis was validated by the expression of Gli2 in 19% of Fsp1
Cre -marked Gli2 WT stromal cells (Fig.  6B) , consistent with our immunofluorescence analyses (Fig. 2, A and B) . The Gli2 nLacZ reporter is expressed within the thin stromal layer that remains in Gli2 DS mice in a pattern similar to that of Gli2 nLacZ within control mice (Fig. 6C) , indicating that these cells may be correctly specified but fail to function normally, owing to loss of GLI2 protein activity. These results collectively show that the Gli2 transcription factor is critical for expression of mammary stem cell niche signals.
Mammatrophic hormone response requires stromal Gli2
Previous studies have shown that MaSCs respond to the mammatrophic hormones estrogen and GH (32, 33) . MaSCs do not, however, express the receptors for these hormones (34) , indicating that the mammatrophic hormone effect is indirect. Mammary stroma is an important mediator of hormone effects on MaSC activity (24), and we find that expression of estrogen receptor and GH receptor is markedly reduced, from 7 and 14%, respectively, to 2% of individual stromal cells in Gli2 DS mice (Fig. 6B) . We therefore examined the
Gli2 dependence of hormone response in FACSisolated Fsp1
Cre -marked mammary stromal cells and indeed found that stimulation with GH or with estrogen revealed significantly impaired induction of their target genes Igf1 or Hgf, respectively, in cells from Gli2 DS as compared to Gli2 WT mice (2.88-fold reduction for Igf1 and 3.16-fold reduction for Hgf; Fig. 6, D and E) , reflecting the significant reduction in expression of receptors for these hormones ( fig. S7 ).
These defects in hormonal response of mammary stroma are reminiscent of the incomplete response of patients suffering from the disorder CPHD to hormonal supplementation. This supplementation is provided because multiple peptidic pituitary hormones and steroidal hormones induced by pituitary hormones are deficient as a result of the congenital hypopituitarism associated with CPHD. Supplementation with GH rescues height defects in these patients (35, 36) , but abnormal breast development often is not improved, even with estrogen supplementation (5). Gli2 DS mice produce normal levels of pituitary hormones such as GH and prolactin (Fig. 4, G and H ;NSG recipient mice. Two months after injection, recipient mice were euthanized for whole-mount analysis. (D) Fsp1-expressing stromal cells rescue mammary duct enlargement, whereas macrophages do not. N = 3 experimental repetitions. (E and F) Mammary glands from Gli2 DS ;NSG recipients with injected donor macrophages and stroma were collected and sectioned for H&E staining, and DSR (ratio of ductal diameter, blue arrow, to total stromal width, yellow arrow) was determined as in Fig. 2 . P < 0.01. Error bars indicate SD. overlap; Fig. 4F ). Despite intact pituitary hormone production, however, Gli2 DS mice nevertheless show abnormal mammary gland development, as described above. Gli2 DS mice thus do not share the pituitary hormonal deficiencies of CPHD patients but do share the resistance to hormone treatments, which likely contributes to the pathogenesis of mammary abnormalities in CPHD patients. Consistent with this interpretation, we find that hGLI2, like mGli2, is expressed predominantly in stromal breast cells ( fig. S8) . If, as our findings suggest, stromal Gli2 mediates hormonal response and the expression of niche signals that support epithelial stem cell activity, it should be possible to rescue mammary defects seen in Gli2 DS mice by providing missing niche signals from an exogenous source. We therefore tested the effect of slow-release polymer implants containing secreted protein signals in the intact mammary of Gli2 DS mice, focusing in particular on insulin-like growth factor 1 (IGF1) and a canonical WNT family protein because of the well-established roles of these signals in mammary development (28) (29) (30) (31) , and using GH as a control. Ex vivo assays showed that GH, IGF1, and WNT2b proteins embedded in the slow-release polymer, poly(ethylene-co-vinyl acetate) (Elvax40), were gradually released over 2 to 8 days and were able to stimulate pathway-specific target genes ( fig. S9 , A to G). For in vivo experiments, the effects of control or factor-containing polymer implants surgically placed in the mammary glands of Gli2 DS mice were assessed after 7 days by wholemount analysis and qPCR (Fig. 7A) . We indeed confirmed, that, although GHcontaining Elvax40 implants increased the number of terminal structures fivefold in Gli2 WT ;NSG host mice (5.625 ± 1.21; fig. S10 , B and C), in Gli2 DS ; NSG mice these implants failed to stimulate Igf1 expression and did not change terminal structure growth at the implantation site (Fig. 7, B to D) . In contrast to GH, IGF1-containing implants increased terminal structure formation in the vicinity of the implants sevenfold in pubertal (psd40) and fivefold in adult (psd70) Gli2 DS mice (Fig. 7 , E and F, and fig. S10A ). IGF1 target genes Egr1 and M-Csf also were reliably induced near the site of the implants (Fig. 7G) , confirming the efficacy of IGF1 delivery. As compared to IGF1 alone, implants containing both IGF1 and WNT2b showed an even greater effect in inducing a 13-fold increase in terminal structure growth at the adult stage (Fig.  7 , H and I) in Gli2 DS mice and consistently induced the expression of M-Csf and Axin2 (Fig. 7J) ; Axin2 expression indicates Wnt response, which promotes the survival and self-renewal ability of mammary epithelia (29) . Together these results suggest that, although the mammary abnormalities in Gli2 DS mice fail to respond to GH stimulation, the terminal growth defects of the mammary ductal tree can be rescued in part by local supplementation with the GLI2-dependent paracrine factors IGF1 and WNT2b.
Conclusions
Although the cellular constitution and signaling activity of the stem cell niche is coming into focus in a variety of tissues, the genetic regulatory were quantified as fold increase relative to control implants. IGF1/WNT2b implants induce more terminal end growth as compared to IGF1 alone. Data are normalized to the mean values in the control and are presented as mean ± SEM; statistical significance was calculated by an unpaired Student's t test (*P < 0.05%, **P < 0.01).
regulator that specifies niche activity in support of mammary epithelial stem cells (Fig. 8) . One aspect of this regulatory activity is the induction, direct or indirect, of stem cell support factors, including IGF and WNT signaling proteins. The GLI2 transcription factor thus appears to control the niche signaling program for MaSCs. Gli2 DS mice lacking stromal Gli2 function consequently suffer from a severe defect in regenerative activity of epithelial stem cells. A second aspect of Gli2 activity is the induction of receptors for mammatrophic hormones such as growth hormone and estrogen in stromal cells such that they become competent to respond to circulating hormones, thereby placing niche signaling activity under hormonal control. This hormonal response is also lost in Gli2 DS mice (Fig. 8) . Thus, our analysis provides insight into the mechanism that coordinates systemic mammatrophic hormone action and activity of the local epithelial stem cell niche, namely, that a single transcription factor, GLI2, controls both the expression of hormone receptors and the stromal niche signaling program. Our findings in Gli2 DS mice imply that a defective stem cell niche environment may underlie the pathogenesis of breast defects seen in the human disorder CPHD. Although several degenerative and aging-related diseases have been tentatively ascribed to defects in stem cells themselves, dysfunction of a supporting niche has not previously been linked to human disease (37) . By indicating that niche failure can cause disease, our study asserts the central role of the niche in controlling stem cell activity and raises the possibility of niche dysfunction in other human diseases. Furthermore, by showing that Gli2-dependent mammary niche signaling factors can rescue aspects of the Gli2 DS mammary in mice, our work suggests a potential therapeutic intervention for patients with hormone-refractory CPHD.
Methods Mice
Female mice at pubertal (5 weeks) or adult (10 weeks) stages were used for all experiments. Gli2 nLacZ mice (38) ;NSG mice. All mouse strains were obtained from Jackson Laboratories, except as otherwise indicated. For each experiment, mice of the same genotypes were randomly selected for experiments and investigators were blinded for outcome assessment. All procedures were performed under an assigned protocol (14586) approved by the Administrative Panel on Laboratory Animal Care (APLAC) at Stanford University.
Antibodies and reagents
The following antibodies were purchased: chicken polyclonal anti-b-Gal antibody (Abcam, CAT:ab9361), rabbit polyclonal anti-CK14 antibody (Covance, CAT:PRB-155P), rabbit polyclonal anti-Ki67 antibody (Abcam, CAT: ab15580), Cy3-conjugated mouse monoclonal anti-smooth muscle actin antibody (Sigma, CAT: C6198), rat anti-CK8 antibody (DSHB, TROMA-I), rabbit polyclonal anticollagen I antibody (Abcam, CAT: ab21286), goat polyclonal anti-NKCC1 antibody (Santa Cruz, CAT:sc-21545), guinea pig anti-Gli2 antibody was obtained from Dr. Eggenschwiler at University of Georgia, APC (allophycocyanin)-conjugated rat anti-mouse F4/80 (Biolegend), rabbit polyclonal anti-S100a4 (Biolegend). Dylight 488-labeled goat anti-chicken IgY, Alexa 488-labeled donkey anti-rabbit immunoglobulin G (IgG) and Alexa 647-labeled donkey anti-goat IgG were purchased from Jackson ImmunoResearch. Alexa 488-labeled goat anti-rabbit IgG, Alexa 594-labeled goat antirabbit IgG, and Alexa 647-labeled goat anti-rat IgG were purchased from Invitrogen. Trichrome straining kit (25088-100) was purchased from Polysciences Inc. Rat/mouse growth hormone enzyme-linked immunosorbent assay (ELISA) kit was purchased from Millipore (EZRMGH-45K). Mouse prolactin ELISA kit was purchased from Abcam (ab100736). Mouse Igf1 ELISA kit was purchased from Raybiotech (ELM-IGF1). Mouse Wnt2B ELISA kit was purchased from MYBioSource (MBS946031). Click-IT®Plus EdU Alexa Fluor®647 flow cytometry assay kit (C10634) was purchased from Invitrogen. Poly(ethylene-co-vinyl acetate) (Elvax40) beads (340502) were purchased from Sigma. Recombinant mouse Igf1 (791-MG-050) and recombinant mouse Wnt2b (customized quantity) were purchased from R&D Systems. Mouse growth hormone (CYT-540) was purchased from Prospecbio. 48.48 Dynamic Array Chips (BMK-M.48.48) for single-cell analysis were purchased from Fluidigm. Ortho-nitrophenyl-b-galactoside (ONPG) was purchased from Thermo-Scientific (catalog no. 34055). TGFbRI/II inhibitor, LY2109761, was purchased from XCESSBIO in a customized quantity.
Mammary cell preparation and flow cytometry
Mammary glands from adult mice (10-week-old) were dissected and minced. Single-cell suspensions were made by digestion of minced tissue with culture medium [Dulbecco's modified Eagle's medium (DMEM)/F12, 5% fetal bovine serum, 1% penicillin-stretomycin-glutamine] containing collagenase/hyaluronidase cocktail solution (StemCell Technolgies, 07912) for 3 hours at 37°C, followed by sequential-5 min treatments with red blood cell lysing buffer (Sigma, R7767), 0.25% trypsin-EDTA, and deoxyribonuclease (0.1 mg/ml) in dispase (0.1 U/ml) with gentle pipetting. Cell suspension was then filtered through 40-mm cell strainers and applied to subsequent FACS isolation. Phycoerythrin (PE)/Cy7-conjugated anti-mouse CD24 (rat, clone M1/69), APC-conjugated anti-mouse CD49f (Rat, clone GoH3), PerCP/Cy5.5 conjugated anti-mouse CD31 (rat, clone 390), PerCP/Cy5.5 conjugated anti-mouse CD45 (rat, clone 30-F11), and PerCP/Cys5.5 conjugated anti-mouseTer119 (rat, TER-119) were purchased from BioLegend. Antibodies were then incubated with strainer-filtered mammary cells in Hanks' balanced salt solution (HBSS) with 2% fetal bovine solution for 20 min on ice. All FACS analysis and cell sortings were performed using FACS aria II (Becton Dickinson).
EdU flow cytometry
In vivo EdU labeling was accomplished by intraperitoneal injection of EdU (150 mg per 10 g of body weight). Mammary glands were collected after 3 hours and prepared as single-cell suspensions, followed by click-it chemistry for EdU staining and surface markers-based staining (CD24-PE/Cy7, CD49f-APC, CD31-PerCP/Cy5.5, CD45-PerCP/Cy5.5, Ter119-PerCP/Cy5.5) to separate stromal, luminal, and basal populations. EdUstained cells in the stromal-negative population were then presented as a percentage of parental cells.
Liquid b-Gal assay FACS-isolated mammary stromal cells were cultured ex vivo and treated with the indicated concentrations of TGFb with or without TGFbRI/II inhibitor, LY2109761. Cells were lysed and incubated with colorimetric b-Gal substrate, orthonitrophenyl-b-galactoside (ONPG). b-Gal activity as indicated by OD 420 was measured at the indicated conditions.
In vitro colony-formation assay
To compare ex vivo colony-forming activity of mammary epithelial cells derived from different backgrounds, we adopted an established 3D OnTop assay (42) . Briefly, Matrigel (BD Bioscience) was thawed and applied to the bottom of 24-well plate at a volume of 120 ml per well, followed by polymerization at 37°C for 15 min. FACS-isolated mammary epithelial cells were resuspended in stock buffer (DMEM/F12, 10% FBS) at a density of 2 × 10 5 cells per ml, serial diluted in Matrigel containing buffer (DMEM/F12, 10% FBS, 50% Matrigel), and plated on top of the polymerized Matrigel. Culture medium was changed every 48 hours. Primary colony numbers were scored after 14 days in culture, followed by sequential phosphate-buffered saline (PBS)-EDTA treatment and extraction of 3D-cultured mammary colonies into single-cell suspensions.
Histology analysis
Gli2
WT and Gli2 DS mice were euthanized at the indicated ages. The 2nd/3rd and/or the 4th mammary glands were dissected. For whole-mount carmine alum analysis, mammary glands were fixed in Carnoy's fixative for 3 hours, followed by serial rehydration, carmine alum staining, and serial dehydration. Mammary glands were then cleared with xylenes and mounted with permount. For whole-mount X-Gal analysis, mammary glands were fixed in X-Gal fixative (2% paraformaldehyde, 0.2% glutaraldehyde) for 30 min at ambient temperature, followed by serial rehydration, overnight carmine alum staining, dehydration, and clearance with xylenes. For X-Gal staining, hematoxylin and eosin (H&E) staining, and trichrome staining, mammary glands were fixed and cut as paraffin sections for H&E or trichrome staining or as cryosections for X-Gal staining. X-Gal, H&E, and trichrome staining on mammary sections was performed as described previously (43) .
Immunofluorescence and confocal microscopy
Dissected mammary glands were fixed in 4% paraformaldehyde, serially dehydrated, and processed as 4-mm paraffin sections. Paraffin sections were cleared with xylenes, rehydrated, and subjected to antigen-retrieval in citric acid-based buffer by the pressure cooker method (44) . For immunostaining, tissue sections were rinsed in PBS, then blocked in blocking solution containing 3% bovine serum albumin (BSA), 0.25% Triton X-100, and serum of the host species used to generate the secondary antibody (10% goat serum or 10% donkey serum). An hour after blocking, diluted primary antibodies in blocking buffer were incubated with sections overnight at 4°C in a humidified chamber. Sections were then washed three times with PBS containing 0.25% Triton X-100 and incubated with appropriate secondary antibodies diluted 1:1000 in blocking solution for 1 hour at ambient temperature, followed by three washes and mounting with Prolong Gold mounting reagent with 4′,6-diamidino-2-phenylindole (DAPI) (Invitrogen). Immunofluorescence images were obtained using a Zeiss LSM 510 inverted confocal microscope, processed for publication with Zeiss LSM5 Image Browser software, and are representative images from one of three experiments.
Mammary fat pad transplantation
FACS-isolated cells were resuspended in a cocktail buffer with 50% DMEM/F12 (20%FBS), 50% Matrigel, and 0.04% Trypan Blue (Sigma). Cells were injected into cleared mammary gland fat pads of 3-week-old female mice. Repopulated mammary glands were harvested 9 weeks after transplantation. Outgrowths of repopulated mammary ductal structures were imaged under a fluorescence dissection microscope (Leica). For macrophage and stromal cell rescue assay, macrophages (identified by F4/80) and Fsp1+ stromal cells (identified by GFP) from the mammary glands of Fsp-cre Gli2 nLacZ/wt mTmG mice were injected into the inguinal fat pads of 3-week-old Gli2 DS NSG recipient mice at 10,000 cells per gland with 50% Matrigel + DMEM F12 medium. Two months after the injection, mammary glands were dissected and analyzed by whole-mount and immunohistochemistry (IHC).
Mammary in vivo competitive repopulation assay
Green color-labeled Lin ) mice. These mixtures were transplanted bilaterally into cleared mammary gland fat pads of immune-deficient NSG mice (non-obese diabetic, severe combined immunodeficiency, IL-2 gamma chain-deficient). Outgrowths in this competitive mammary repopulation assay were examined 9 weeks after transplantation. Slow-release polymer implantation assay GH, IGF1, and IGF1/WNT2B were prepared as slow-release proteins in Elvax40-based polymers (47) (48) (49) . Briefly, lyophilized BSA (20 mg) alone or in a mixture with the indicated amount of GH, IGF1, or IGF1/WNT2B were dispersed in 0.125 ml of Elvax40 that had been dissolved in dichloromethane (20% wt/vol). The mixture was quickfrozen and dried in a rotary evaporator, then the polymer matrix with entrapped proteins was cut to size (0.5 to 1 mg) and surgically implanted. Kinetics and activities of released proteins were validated in ELISA analyses and in qPCR analyses of their target gene expression, respectively. Control Elvax40 polymer or Elvax40 polymers containing the above-mentioned proteins were
